Whats VC of Anergis going to do?
say.. "oh we used up 55 million Euros of investor money, but now we just need 13 million more to restart trials, but we can't get it to pay MYMX licensing agreement so we are just going to quit and forget about COP-Virosomes that we just paid 110k extension on the LCA and had Stallergenes Greer do a years worth of pre-clinical studies on. I guess those who put up 55 million are shit out of luck. Onward with Tolly's"
I Highly do not think that will be the case.
in my opinion it will be either:
1. They sign another extension to have more time to raise the funds.
2. They have the funds and are preparing to release.
or
3. We are surprised by a third party entering the deal. (i.e. Stallergenes wants a piece) And the terms of the deal are completely different than what we imagined.
In my opinion, Mymetics is in the captains seat, bc if you remember they get paid MORE the longer this goes on, and according to the things we have learned.. the Anergis COP's don't really cut it alone in clinical trials... they are good, but not good enough... They need the combination of the COP-Virosome to "Cure" the allergy. And imo. Anergis is not going to put another 3 years into searching for another candidate to compliment their COP's when they have already found one that works.
"The results showed that a treatment with COP-virosomes was able to cure allergic asthma in birch pollen sensitized mice.
The COP-virosomes were significantly superior to the COP or the virosome alone, confirming the synergy between COP and virosomes to foster an improved second generation AIT treatment."
From the May 15th 10Q.
"Anergis is investigating the possibility to fund a license agreement with Mymetics, but for now nothing is confirmed. "
Sounds to me like Anergis could flat out pay for it themselves.
and this 10q came out BEFORE the stallergenes pre-clinical results.
The Stallergenes results came out on May 28th.
So what's the hold up? well, we can only speculate.
But also I assume Anergis will not see their 55 million investment and over 10 years of work, and patented COP technology go to waste.
If they weren't going to do it, I doubt they'd even have released the PR about it in conjunction with Stallergenes and Mymetics. VC going to get that money imo.
My question is ... Were the pre-clinical testing with Stallergenes considered the Toxicology studies? because if they were. then IF they sign the deal, that puts MYMX right into phase 2A according to VC in the Sachs video comments.
$MYMX
News 
Market Data 
Discover 
